Clinical Trials Logo

Clinical Trial Summary

Perioperative fluid management in abdominal surgery is a subject of controversy and current standard fluid therapy is not evidence based. Compensating decreasing blood pressure by volume substitution is common praxis. Alternatively the fall in blood pressure due to vasodilatation can be corrected by applying vasoactive agents. A review of the data on the effect of "high volume" perioperative fluid therapy suggests that overhydration may have deleterious effects on cardiopulmonary function as well as on recovery of gastrointestinal motility, tissue oxygenation and wound healing. Restrictive fluid administration in fast-track surgery led to no differences in all-over recovery after colonic surgery. Based on our current knowledge, a low volume regimen combined with a noradrenaline perfusor may be of benefit during open radical cystectomy. It seems of interest and safe to use a noradrenaline perfusor combined with a low volume regimen during open radical cystectomy. The low volume regimen, as described in this study protocol, is well established at our institution, which has a large experience in cystectomy.

The aim of this study is to compare intraoperative blood loss, quality of the surgical field, metabolic response, pain relief, fatigue score, gastrointestinal function, cardiovascular, pulmonary, infectious and surgical complications as well as cognitive function in two groups of patients undergoing radical cystectomy.

The investigators expect a lower complication rate in the restrictive fluid regimen group and better surgical conditions. This could significantly affect short- and long-term outcome of patient undergoing major cancer surgery, have an impact on survival and financial consequences.


Clinical Trial Description

Background

Perioperative fluid management in abdominal surgery is a subject of controversy and current standard fluid therapy is not evidence based. Standard fluid therapy includes replacement of basic fluid requirements, loss by perspiration, by exsudation through the surgical wound, and loss into the third space.

Fluid preload before spinal or just after epidural anaesthesia is a common and recognized practice in clinical anaesthesia. Vasodilatation is a well-known side effect of halogenics, of most hypnotics and opiates. Compensating decreasing blood pressure by volume substitution is common praxis. Alternatively the fall in blood pressure due to vasodilatation can be corrected by applying vasoactive agents. A review of the data on the effect of "high volume" perioperative fluid therapy suggests that overhydration may have deleterious effects on cardiopulmonary function (excessive shift to the right on the Starling myocardial performance curve, pneumonia and respiratory failure) as well as on recovery of gastrointestinal motility (prolonged postoperative ileus (PI)), tissue oxygenation and wound healing (anastomosis leakage). A postoperative weight gain of 3-7 kg in patients after major elective surgery therefore seems to represent a genuine fluid overload. Delay in bowel motility may be due to the presence of excess fluid in the intestinal wall resulting from excess perioperative fluid therapy. Increased gut permeability after surgical trauma may also contribute to the development of PI because of enhanced uptake of luminal bacterial products. Postoperative complications were significantly reduced by restricted fluid therapy. A dose response relation between administrated fluid volume and postoperative complications (cardiopulmonary and tissue healing) was found in a randomised assessor blinded multicenter trial for colorectal surgery 11,12. The restricted fluid regimen did not lead to haemodynamic instability and the amount of vasoactive substances administered was similar. No significant difference in urinary output was demonstrated on days 1 and 6. Restrictive fluid administration in fast-track surgery led to no differences in all-over recovery after colonic surgery. Goal-directed intraoperative fluid administration using the oesophageal Doppler monitor to maintain maximal stroke volume has been shown to reduce the length of hospital stay, lower the incidence of postoperative nausea and vomiting and to encourage an early return of bowel function. Oesophageal Doppler monitor permits rapid, minimally invasive and continuous estimation of cardiac output. It can be easily inserted and is not associated with major complications. The investigators will use oesophageal Doppler monitoring for intraoperative monitoring of stroke volume and cardiac output.

In animal experiments on pigs, high (18ml/kg/h) or low (3ml/kg/h) volume crystalloid fluid treatment had no effect on colon tissue oxygenation tension. Three different fluid volume regimens (3ml/kg/h, 7 ml/kg/h and 20ml/kg/h) tested did not affect tissue oxygen pressure in the jejunum and colon, suggesting efficient autoregulation of intestinal blood flow in healthy pigs undergoing uncomplicated abdominal surgery 25. Noradrenaline increased systemic blood flow (mean arterial pressure and cardiac index) and failed to increase microcirculatory blood flow in most abdominal organs in septic pigs. Thoracic epidural anesthesia per se does not affect intravascular volume. Therefore, vasopressors are preferable for treatment of hypotension after epidural anesthesia.

The incidence of postoperative cognitive dysfunction varies greatly with reported rates of 10% to 55%. Patient characteristics such as age, education, type and length of surgical procedure and preoperative cognitive status have been found to affect the incidence and severity of postoperative cognitive dysfunction. The influence of intraoperative volume management on cognitive function has not been assessed.

It seems of interest and safe to use a noradrenaline perfusor combined with a low volume regimen during open radical cystectomy. The low volume regimen, as described in this study protocol, is well established in our institution, which has a large experience in cystectomy.

Objective

The aim of this study is to compare intraoperative blood loss, quality of the surgical field (defined later), metabolic response, pain relief, fatigue score, gastrointestinal function, cardiovascular, pulmonary, infectious and surgical complications and cognitive function in two groups of patients undergoing radical cystectomy. The first group will be treated according to an internationally accepted standard fluid regimen (6 ml/kg/h of crystalloids and correction of the hypotony with fluid boluses); the second one will be treated with a restrictive fluid regimen of 2ml/kg/h of crystalloids in combination with sympathicomimetics.

Methods

Prospective, randomised, controlled, single-centre study. Randomly assigned in equal proportion by computer to receive the dry regimen 2ml/kg/h combined with sympathicomimetics or the standard fluid management.

An advanced balanced electrolyte solution will be used containing acetate/malate instead of lactate. Substantial advantages are a base excess of +/- O mmol/l, that it is isotonic, and contains anions acetate and malate.

208 patients with open radical cystectomy Duration: 36 months Setting: University Department of Urology , Inselspital Bern, Switzerland Study sample and power calculation

A power analysis for postoperative complication rate as primary outcome has been done with the NCSS PASS programme:

Power: 80% Significance: 0.05% or lower Complication rate for the restrictive volume regimen group: 20% Complication rate for the control group: 38% 83 patients will be required in each group. Assuming a 20% drop-out rate 104 patients per group will be enrolled. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01276665
Study type Interventional
Source University Hospital Inselspital, Berne
Contact
Status Completed
Phase N/A
Start date November 2009
Completion date December 2012

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06034015 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers Phase 1
Recruiting NCT04235764 - En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
Completed NCT02371447 - VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer Phase 1/Phase 2
Recruiting NCT04081246 - Transurethral Modified En Bloc Resection For Large Bladder Tumours. N/A
Recruiting NCT06059547 - Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer Phase 2
Terminated NCT04779489 - Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer N/A
Not yet recruiting NCT04493489 - Propranolol Adjuvant Treatment of Bladder Cancer Phase 2
Completed NCT03520231 - Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases Phase 2
Recruiting NCT04537221 - Nordic Cystectomy Study III - Transfusion
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT01955408 - Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment N/A
Completed NCT04487457 - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05562791 - A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer Phase 1
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Completed NCT02781428 - To Detect the Sensitivity of the UroMark Assay
Recruiting NCT04738630 - Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer Phase 2
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Active, not recruiting NCT03978624 - Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer Phase 2
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A